Patient Care, In the Media
Patient Power: Perlmutter Cancer Center Hematologist Discusses Treatment Options for People with High-Risk Myeloma
Photo: OGphoto/Getty
People with ultra-high-risk multiple myeloma may respond poorly to treatment, relapse quickly after they have had chemotherapy, and have a poor prognosis. However, new treatment options such as chimeric antigen receptor (CAR) T-cell therapy and bispecific antibody approaches are showing promise for these patients, says Gareth J. Morgan, MD, PhD, professor in the Department of Medicine at NYU Grossman School of Medicine and director of multiple myeloma research at NYU Langone Health's Perlmutter Cancer Center.
"The results we see in relapsed/refractory patients with these agents really suggest they're going to be game changers for ultra-high-risk myeloma," Dr. Morgan says. "And it's making me very excited for the change that it's going to bring about for patients."
Watch and read more from Patient Power.
Gareth J. Morgan, MD, PhD
Perlmutter Cancer Center
Perlmutter Cancer Center Education & Research
Patient Care, In the Media, Translational Medicine
STAT: Perlmutter Cancer Center Hematologist–Oncologist Discusses Promising New Treatment for Multiple Myeloma
More than 70 percent of people in the clinical trial responded to the drug.
NCI Cancer Currents Blog: Perlmutter Cancer Center Medical Oncologist Discusses New Treatment for Multiple Myeloma
Dr. Faith E. Davies discusses the approval of second CAR T-cell therapy for multiple myeloma.